A Phase 3 clinical study investigating Liraglutide for subjects with Type 2 Diabetes Mellitus treated with basal insulin completed its primary data collection on 2026-02-07. The trial, comparing GZR4 to insulin degludec, enrolled 620 participants.
Background
The study focuses on Type 2 Diabetes Mellitus (T2DM), a chronic condition affecting glucose metabolism. This trial aims to assess the efficacy and safety of GZR4 in subjects already on basal insulin therapy, providing a comparison against insulin degludec.
Trial design
The study (NCT06767748) is a Phase 3 clinical trial that enrolled 620 subjects with Type 2 Diabetes Mellitus who are treated with basal insulin. The trial is designed to compare the efficacy, safety, and patient-reported outcomes of once-weekly GZR4 against once-daily Insulin Degludec, with or without non-insulin antidiabetic agents.
What this means
The primary completion of this Phase 3 study signifies that the main data collection period has concluded. This milestone precedes the data analysis phase, where researchers will evaluate the efficacy, safety, and patient-reported outcomes of GZR4 compared to insulin degludec in the studied population. The findings from this trial will be crucial for understanding the potential role of GZR4 in the management of Type 2 Diabetes Mellitus.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT06767748, titled "A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin," was updated on 2026-02-07 on clinicaltrials.gov.